Development of agonists and antagonists of MCJ, molecule for mitochondria respiration
Mitotherapeutix aims to develop novel therapeutics based on new discoveries in the control of cellular metabolism particularly in key mitochondria regulators. One of the targets that Mitotherapeutix is currently pursuing is MCJ, a key regulator of mitochondria respiration. Mitotherapeutix is actively working in the development of agonists for this molecule to overcome chemo-resistance in breast cancer and many other cancers that demonstrate a poor response to chemotherapy. In parallel, Mitotherapeutix has developed antagonists of MCJ to accelerate mitochondrial metabolism as a strategy to target liver diseases such NAFLD, NASH and cirrhosis. Both cancer chemo-resistance and liver diseases represent enormous unmet medical needs that desperately need solutions.
Bob Hennessey, CEO
Bob Hemley, COO